Managing Anticoagulant Patients Undergoing Dental Extraction by using Hemostatic Agent: Tranexamic Acid Mouthrinse.
Anticoagulant therapy
antiplatelet therapy
hemostatic agent
tranexamic acid
Journal
Journal of pharmacy & bioallied sciences
ISSN: 0976-4879
Titre abrégé: J Pharm Bioallied Sci
Pays: India
ID NLM: 101537209
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
03
10
2020
accepted:
04
10
2020
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
ppublish
Résumé
Patient who is on antiplatelet therapy had an impaired fibrin formation which leads to fibrinolysis which is the main reason behind postextraction bleeding. The aim of the study is to manage anticoagulated patient who has to undergo dental extraction by using hemostatic agent and the objective is to rule out potential risk factor which may trigger bleeding. One hundred patients with anticoagulant and antiplatelet therapy and having International Normalized Ratio (INR) in-between 1.9 and 3.5 were selected. Postextraction instruction use 5 ml of 10% tranexamic acid mouthrinse four times a day for next 7 days was suggested. All demographic data, history of anticoagulant and antiplatelet therapy, details of bleeding, and treatment requirement were recorded to identify potential risk factor. Of 100 subjects, 16 were reported postextraction bleeding on days 1 and 2 which was controlled by tranexamic acid pressure pack. Bleeding from extraction socket of 10 patients was stopped by gelatin foam. No life-threatening risk was observed. In patients with age group of 41-60 years whose INR value was ≥2.5, the number of teeth undergoing extraction, whose bleeding time was increased, and were on long duration of antiplatelet and anticoagulation therapy might increase the risk of bleeding. Use of tranexamic acid mouthrinse after extraction is an effective way to control bleeding on patients who are under antiplatelet therapy with at therapeutic INR level is a secure and allowable method of minimizing postextraction oozing.
Sections du résumé
BACKGROUND
BACKGROUND
Patient who is on antiplatelet therapy had an impaired fibrin formation which leads to fibrinolysis which is the main reason behind postextraction bleeding.
OBJECTIVES
OBJECTIVE
The aim of the study is to manage anticoagulated patient who has to undergo dental extraction by using hemostatic agent and the objective is to rule out potential risk factor which may trigger bleeding.
METHODS
METHODS
One hundred patients with anticoagulant and antiplatelet therapy and having International Normalized Ratio (INR) in-between 1.9 and 3.5 were selected. Postextraction instruction use 5 ml of 10% tranexamic acid mouthrinse four times a day for next 7 days was suggested. All demographic data, history of anticoagulant and antiplatelet therapy, details of bleeding, and treatment requirement were recorded to identify potential risk factor.
RESULTS
RESULTS
Of 100 subjects, 16 were reported postextraction bleeding on days 1 and 2 which was controlled by tranexamic acid pressure pack. Bleeding from extraction socket of 10 patients was stopped by gelatin foam. No life-threatening risk was observed. In patients with age group of 41-60 years whose INR value was ≥2.5, the number of teeth undergoing extraction, whose bleeding time was increased, and were on long duration of antiplatelet and anticoagulation therapy might increase the risk of bleeding.
CONCLUSION
CONCLUSIONS
Use of tranexamic acid mouthrinse after extraction is an effective way to control bleeding on patients who are under antiplatelet therapy with at therapeutic INR level is a secure and allowable method of minimizing postextraction oozing.
Identifiants
pubmed: 34447136
doi: 10.4103/jpbs.JPBS_639_20
pii: JPBS-13-469
pmc: PMC8375824
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S469-S472Informations de copyright
Copyright: © 2021 Journal of Pharmacy and Bioallied Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Oral Maxillofac Surg. 2005 Apr;63(4):540-5
pubmed: 15789328
J Am Dent Assoc. 2000 Jan;131(1):77-81
pubmed: 10649877
N Engl J Med. 1997 May 22;336(21):1506-11
pubmed: 9154771
N Engl J Med. 2003 Aug 14;349(7):675-83
pubmed: 12917305
Surg Clin North Am. 2005 Dec;85(6):1179-89, x
pubmed: 16326201
J Mass Dent Soc. 2002 Winter;50(4):44-50
pubmed: 12874912
J Intensive Care. 2017 Jan 20;5:5
pubmed: 28729903
Am J Med. 2012 Feb;125(2):183-9
pubmed: 22269622
Oral Surg Oral Med Oral Pathol. 1990 Sep;70(3):274-7
pubmed: 2145537
J Oral Maxillofac Surg. 1993 Nov;51(11):1211-6
pubmed: 8229393
Br J Oral Maxillofac Surg. 1998 Dec;36(6):480
pubmed: 9881796
Br J Oral Maxillofac Surg. 2002 Jun;40(3):248-52
pubmed: 12054719
Oral Surg Oral Med Oral Pathol. 1993 Jan;75(1):29-31
pubmed: 8419869
N Engl J Med. 1989 Mar 30;320(13):840-3
pubmed: 2648144
Arch Intern Med. 1998 Aug 10-24;158(15):1610-6
pubmed: 9701094
Chest. 2001 Jan;119(1 Suppl):8S-21S
pubmed: 11157640